Cargando…
Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders
Autores principales: | Villoutreix, Bruno O., Beaune, Philippe H., Tamouza, Ryad, Krishnamoorthy, Rajagopal, Leboyer, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315962/ https://www.ncbi.nlm.nih.gov/pubmed/32593662 http://dx.doi.org/10.1016/j.drudis.2020.06.022 |
Ejemplares similares
-
Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities
por: Villoutreix, Bruno O, et al.
Publicado: (2021) -
Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context
por: Tamouza, Ryad, et al.
Publicado: (2021) -
IL6/IL6R genetic diversity and plasma IL6 levels in bipolar disorder: An Indo-French study
por: Sundaresh, Aparna, et al.
Publicado: (2019) -
HLA-class II haplotypes and Autism Spectrum Disorders
por: Bennabi, Meriem, et al.
Publicado: (2018) -
A bipolar disorder patient becoming asymptomatic after adjunctive anti-filiarasis treatment: a case report
por: Hamdani, Nora, et al.
Publicado: (2013)